Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data.
Doping in Sports
/ methods
Glycine
/ administration & dosage
Humans
Hypoxia-Inducible Factor 1
/ agonists
Hypoxia-Inducible Factor-Proline Dioxygenases
/ administration & dosage
Isoquinolines
/ administration & dosage
Male
Middle Aged
Pilot Projects
Retrospective Studies
Substance Abuse Detection
/ methods
HIF activator
IOX-2
human urine
roxadustat
sports drug testing
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
15
07
2020
revised:
11
08
2020
accepted:
12
08
2020
pubmed:
19
8
2020
medline:
1
10
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Early in 2020, racehorse doping cases revolved around the hypoxia-inducible factor (HIF) activator IOX-2. While the composition of IOX-2 has also been known and monitored in human doping controls for several years, the testing capability of routine sports drug testing methods was revisited for this newly surfaced doping agent. IOX-2 and the analytically well-established HIF activator roxadustat (FG-4592) share identical precursor/product ion pairs, enabling their co-detection in existing initial testing procedures in routine doping controls for the intact unconjugated analytes. In addition, hydroxylated IOX-2 and the corresponding glucuronic acid conjugates were identified as major metabolites in a microdose elimination study, contributing to enhanced initial testing and confirmation procedures.
Substances chimiques
Hypoxia-Inducible Factor 1
0
Isoquinolines
0
Hypoxia-Inducible Factor-Proline Dioxygenases
EC 1.14.11.29
Glycine
TE7660XO1C
roxadustat
X3O30D9YMX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1614-1619Subventions
Organisme : Manfred-Donike Institute for Doping Analysis
Organisme : Federal Ministry of the Interior, Building and Community of the Federal Republic of Germany
Organisme : National Anti-Doping Agency
Informations de copyright
© 2020 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
World Anti-Doping Agency. The world anti-doping code - international standard: prohibited list 2020. Available at: https://www.wada-ama.org/sites/default/files/wada_2020_english_prohibited_list_0.pdf Accessed: 10 July 2020
Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal. 2012;4(11):830-845.
Synthetic doping agent detected in two Standardbreds. Available at: https://www.thoroughbreddailynews.com/synthetic-doping-agent-detected-in-two-standardbreds (Accessed: 23 January 2020)
Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal. 2016;121:181-187.
Görgens C, Guddat S, Thomas A, et al. Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. J Pharm Biomed Anal. 2016;131:482-496.
World Anti-Doping Agency. International standard for laboratories (ISL 10.0). Available at: https://www.wada-ama.org/sites/default/files/resources/files/isl_nov2019.pdf (Accessed: 10 August 2020)
World Anti-Doping Agency. Technical document on the minimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes (TD IDCR). Available at: https://www.wada-ama.org/sites/default/files/resources/files/td2015idcr_-_eng.pdf (Accessed: 10 July 2020)
Eichner D, Van Wagoner RM, Brenner M, et al. Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test Anal. 2017;9:1768-1778.
Akizawa T, Yamaguchu Y, Otsuka T, Reusch M. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of Roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis. Nephron. 2020;144(8):372-382.